Mechanism of action
Magnesium sulfate exerts multiple physiologic effects through several mechanisms. As an NMDA receptor antagonist, it blocks glutamate-mediated excitatory neurotransmission in the central nervous system, producing anticonvulsant effects. This is the primary mechanism underlying its efficacy in eclampsia.
Magnesium acts as a physiologic calcium channel blocker, competing with calcium at voltage-gated calcium channels in vascular smooth muscle and myometrium. This reduces calcium influx, leading to vasodilation and uterine relaxation, which explains its use as a tocolytic and its blood pressure-lowering effects in preeclampsia.
At the neuromuscular junction, magnesium decreases acetylcholine release from presynaptic terminals and reduces motor end-plate sensitivity to acetylcholine. This accounts for the loss of deep tendon reflexes and potential respiratory muscle weakness at toxic concentrations.
In cardiac tissue, magnesium stabilizes cell membranes and is essential for normal potassium channel function. It suppresses early afterdepolarizations and is particularly effective in terminating torsades de pointes, a polymorphic ventricular tachycardia associated with QT prolongation.
Magnesium also acts as a cofactor for over 300 enzymatic reactions, including ATP-dependent processes, protein synthesis, and nucleic acid stability. Replacement corrects the metabolic derangements associated with hypomagnesemia.
- Magnesium sulfate is first-line for eclampsia prevention and treatment, superior to phenytoin and benzodiazepines
- Mechanism: NMDA antagonist, physiologic calcium channel blocker, decreases ACh release at NMJ
- Loss of patellar reflexes (8-12 mEq/L) is earliest sign of toxicity; respiratory depression occurs at >12 mEq/L
- Calcium gluconate 1g IV is the antidote for magnesium toxicity causing respiratory or cardiac depression
- Magnesium sulfate terminates torsades de pointes even when serum magnesium levels are normal
- Hypomagnesemia causes refractory hypokalemia and hypocalcemia; must correct magnesium first
- Contraindicated in myasthenia gravis (worsens neuromuscular blockade) and severe renal failure
- Standard eclampsia regimen: 4-6g IV load, then 1-2g/hour maintenance for 24 hours postpartum
Indications
Obstetric uses
Eclampsia and severe preeclampsia represent the most important indication. Magnesium sulfate is first-line therapy for seizure prophylaxis in severe preeclampsia and for treatment of eclamptic seizures. It reduces the risk of recurrent seizures by 50-60% compared to phenytoin or diazepam. The Magpie trial established its role in preventing progression from severe preeclampsia to eclampsia.
Tocolysis for preterm labor between 24-32 weeks gestation is used to delay delivery for 48 hours, allowing time for corticosteroid administration for fetal lung maturity. Magnesium sulfate is not a first-line tocolytic in current guidelines but remains in use at many centers.
Fetal neuroprotection is an emerging indication. Administration to women at imminent risk of preterm delivery before 32 weeks reduces the risk of cerebral palsy and gross motor dysfunction in surviving infants.
Cardiovascular uses
Torsades de pointes associated with prolonged QT interval responds rapidly to intravenous magnesium sulfate, which stabilizes cardiac membranes and shortens the QT interval. This is effective even in patients with normal serum magnesium levels.
Acute myocardial infarction was previously studied for magnesium supplementation, but large trials showed no mortality benefit, and it is no longer routinely recommended.
Electrolyte replacement
Hypomagnesemia from any cause requires replacement. Common causes include diuretic use, chronic diarrhea, malabsorption, chronic alcoholism, and drugs like proton pump inhibitors and aminoglycosides. Severe hypomagnesemia causes concurrent hypokalemia and hypocalcemia that are refractory to replacement until magnesium is corrected.
Other uses
Magnesium sulfate is used in severe asthma exacerbations as an adjunct bronchodilator when standard therapy fails. It may also be used as a cathartic (laxative) when taken orally, and topically in Epsom salt soaks for minor inflammation.
Pharmacokinetics
Magnesium sulfate is administered intravenously or intramuscularly for systemic effects. The oral route has poor bioavailability and produces a cathartic effect; oral absorption is approximately 30-40% and is used primarily for bowel preparation or laxative purposes.
Distribution is primarily extracellular. Only 1-2% of total body magnesium is in serum; the remainder is intracellular or in bone. Magnesium crosses the placenta, achieving fetal serum levels approximately 70-100% of maternal levels. It also appears in breast milk.
Onset of action after intravenous administration is immediate, with anticonvulsant effects apparent within minutes. Intramuscular administration produces therapeutic levels within 60 minutes. Duration of action is 30 minutes after IV bolus, necessitating continuous infusion for sustained effect.
Elimination is entirely renal. The kidneys filter magnesium freely at the glomerulus, and 95-98% is reabsorbed in the loop of Henle and distal tubule under normal conditions. During magnesium loading, renal excretion increases proportionally. The elimination half-life is approximately 4 hours in patients with normal renal function.
Therapeutic range for eclampsia prophylaxis is 4-8 mEq/L (4.8-9.6 mg/dL). Loss of deep tendon reflexes occurs at 8-12 mEq/L, respiratory depression at 12-15 mEq/L, and cardiac arrest at levels exceeding 15-18 mEq/L.
Renal impairment dramatically prolongs magnesium elimination and increases toxicity risk. Dose reduction and close monitoring are essential when creatinine clearance is below 30 mL/min.
Adverse effects
Adverse effects are dose-dependent and correlate with serum magnesium levels. Close monitoring of clinical signs and serum levels is essential during infusion.
Common adverse effects
Flushing and warmth occur in most patients receiving intravenous magnesium due to peripheral vasodilation. Nausea and diaphoresis are also common, particularly with bolus administration. These effects are generally mild and do not require treatment discontinuation.
Hypotension results from systemic vasodilation and can be significant, particularly when combined with other antihypertensive agents. Slower infusion rates reduce this risk.
Serious adverse effects
Loss of deep tendon reflexes is the earliest clinical sign of magnesium toxicity, occurring at levels of 8-12 mEq/L. Absent patellar reflexes should prompt immediate evaluation of serum magnesium levels and consideration of dose reduction or discontinuation.
Respiratory depression occurs at serum levels above 12 mEq/L due to weakness of respiratory muscles and central respiratory drive suppression. This is the most serious complication and can progress to respiratory arrest.
Cardiac effects include bradycardia, heart block, and ultimately cardiac arrest at very high levels (>15 mEq/L). ECG changes include PR prolongation and QRS widening.
Neuromuscular blockade can be profound at toxic levels, producing skeletal muscle weakness and paralysis. This effect is potentiated by concurrent use of neuromuscular blocking agents.
Fetal and neonatal effects
Maternal magnesium sulfate crosses the placenta. Neonatal hypermagnesemia can cause hypotonia, respiratory depression, and feeding difficulties in newborns delivered during or shortly after maternal magnesium therapy. These effects are usually transient but may require supportive care.
Treatment of toxicity
Calcium gluconate (10 mL of 10% solution IV over 3 minutes) is the antidote for magnesium toxicity. Calcium directly antagonizes magnesium's effects at neuromuscular and cardiac sites. Supportive care includes discontinuation of magnesium, mechanical ventilation if needed, and hemodialysis in severe cases with renal impairment.
Contraindications and warnings
Absolute contraindications
Myasthenia gravis is an absolute contraindication. Magnesium sulfate worsens neuromuscular blockade and can precipitate myasthenic crisis with respiratory failure.
Heart block or significant cardiac conduction abnormalities preclude use, as magnesium can worsen AV conduction delays and precipitate complete heart block.
Renal failure with severe impairment (GFR <30 mL/min) dramatically increases toxicity risk due to impaired elimination. If magnesium must be used, drastically reduced doses with frequent level monitoring are mandatory.
Relative contraindications and warnings
Hypocalcemia potentiates magnesium's effects on neuromuscular transmission and cardiac conduction. Correct calcium levels before initiating therapy when possible.
Concurrent neuromuscular blocking agents show synergistic effects with magnesium. Reduced doses of neuromuscular blockers are necessary, and prolonged paralysis can occur.
Maternal use near delivery requires preparation for neonatal resuscitation, as newborns may exhibit hypermagnesemia with respiratory depression and hypotonia.
Monitoring requirements
During intravenous infusion, monitor:
- Deep tendon reflexes every 1-2 hours (patellar reflex most reliable)
- Respiratory rate and oxygen saturation continuously
- Urine output to ensure adequate renal function (maintain >25-30 mL/hour)
- Serum magnesium levels every 4-6 hours during loading, then daily during maintenance
- Cardiac monitoring for arrhythmias and conduction disturbances
Calcium gluconate should be immediately available at the bedside whenever magnesium sulfate is administered intravenously.
Drug interactions
Neuromuscular blocking agents
Aminoglycoside antibiotics and nondepolarizing neuromuscular blockers (rocuronium, vecuronium, cisatracurium) demonstrate potentiated neuromuscular blockade when combined with magnesium sulfate. Magnesium decreases acetylcholine release and reduces motor end-plate sensitivity, requiring dose reduction of paralytic agents by 25-50%.
Cardiovascular medications
Calcium channel blockers (nifedipine, amlodipine) show additive effects with magnesium sulfate, potentially causing severe hypotension and cardiac depression. This combination is particularly relevant in preeclampsia management, where nifedipine is commonly used. Monitor blood pressure closely and reduce doses of both agents if combined.
Cardiac glycosides (digoxin) have increased toxicity risk in the presence of hypomagnesemia. However, acute magnesium administration does not significantly alter digoxin levels or effects.
Central nervous system depressants
Combination with opioids, benzodiazepines, or barbiturates increases the risk of respiratory depression through additive CNS depressant effects. Use caution and monitor respiratory function closely.
General anesthetics potentiate magnesium's neuromuscular blocking effects. Anesthesiologists must be informed of recent magnesium sulfate administration.
Antibiotics
Aminoglycosides (gentamicin, tobramycin) both cause hypomagnesemia through renal wasting and potentiate magnesium's neuromuscular blocking effects. This creates a complex interaction requiring close monitoring.
Diuretics
Loop diuretics (furosemide) and thiazide diuretics increase renal magnesium excretion, potentially causing hypomagnesemia during chronic use. Conversely, they may reduce magnesium toxicity risk during acute magnesium sulfate infusion.
Absorption interactions
Oral magnesium binds to tetracyclines, fluoroquinolones, and bisphosphonates, reducing their absorption. Separate administration by at least 2-4 hours.
Magnesium-containing antacids can reduce absorption of levothyroxine, iron supplements, and certain antimalarial drugs.
Clinical pearls
Check the reflexes first. Before each magnesium dose or infusion rate increase, assess patellar deep tendon reflexes. Absent reflexes mean the patient is approaching toxic levels, even if respiratory function appears normal. This is the most practical bedside monitoring tool.
Magnesium corrects refractory hypokalemia. When potassium replacement fails to correct hypokalemia despite adequate supplementation, check magnesium levels. Hypomagnesemia impairs potassium reabsorption in the renal tubules. Correcting magnesium allows successful potassium repletion.
The Magpie trial changed practice. This landmark 2002 multicenter trial demonstrated that magnesium sulfate reduces eclampsia risk by 58% and maternal death by 50% compared to placebo in severe preeclampsia. It established magnesium as standard of care, superior to phenytoin and diazepam.
4-gram loading dose, 1-2 gram/hour maintenance is the standard eclampsia prophylaxis regimen. This achieves therapeutic levels of 4-8 mEq/L. Continue for 24 hours postpartum or 24 hours after last seizure.
Calcium gluconate is the antidote. Keep 10 mL of 10% calcium gluconate (1 gram) at bedside during magnesium infusion. Give IV over 3 minutes for respiratory depression, cardiac arrhythmias, or absent reflexes with clinical deterioration.
Torsades responds when nothing else works. Even with normal serum magnesium levels, IV magnesium sulfate (2 grams over 1-2 minutes) terminates torsades de pointes more reliably than other antiarrhythmics. It stabilizes cardiac membranes and suppresses triggered activity.
PPIs cause chronic hypomagnesemia. Proton pump inhibitors interfere with intestinal magnesium absorption through unclear mechanisms. Consider checking magnesium levels in patients on chronic PPIs who develop fatigue, muscle cramps, or arrhythmias.
Alcoholics need magnesium first. In chronic alcoholism with multiple electrolyte deficiencies, repleting magnesium enables correction of concurrent hypokalemia and hypocalcemia. Alcohol causes renal magnesium wasting and poor dietary intake.
Reduced maintenance dose in renal impairment. Even mild renal impairment (GFR 30-60) requires dose reduction and more frequent level monitoring. Calculate creatinine clearance before starting therapy in any patient with baseline renal disease.
Neonatal effects are transient. Newborns delivered during maternal magnesium therapy may show hypotonia and poor feeding for 24-48 hours. These effects resolve as neonatal magnesium is eliminated. Severe cases require supportive care but rarely need calcium administration.
For magnesium toxicity progression: 4-8-12-16 rule: 4-8 mEq/L therapeutic, 8-12 lost reflexes, 12-15 respiratory depression, >15 cardiac arrest
Practice questions
1. A 32-year-old woman at 36 weeks gestation presents with severe headache, visual changes, and blood pressure of 180/115 mmHg. Urinalysis shows 4+ proteinuria. She is started on magnesium sulfate infusion for seizure prophylaxis. Four hours later, the nurse reports that the patient has absent patellar reflexes but is breathing normally at 14 breaths per minute. What is the most appropriate next step?
2. A 58-year-old man with history of chronic alcohol use disorder is admitted for pneumonia. Laboratory studies show: potassium 2.9 mEq/L, magnesium 1.1 mEq/L (normal 1.7-2.2), calcium 7.8 mg/dL. Despite receiving 80 mEq of potassium chloride over 24 hours, repeat potassium remains 3.0 mEq/L. Which of the following best explains the refractory hypokalemia?
3. A 45-year-old woman with cirrhosis and prolonged QT interval develops polymorphic ventricular tachycardia consistent with torsades de pointes. She is hemodynamically stable. Serum magnesium level drawn 2 hours ago was 2.0 mEq/L (normal 1.7-2.2). Which of the following is the most appropriate initial treatment?
Frequently asked questions
How does magnesium sulfate work for eclampsia?
Magnesium sulfate prevents and treats eclamptic seizures primarily by antagonizing NMDA receptors in the central nervous system, blocking excitatory glutamate neurotransmission. It also acts as a physiologic calcium channel blocker, reducing calcium influx into neurons and stabilizing cell membranes. Additionally, magnesium causes vasodilation that may reduce cerebral edema. These mechanisms make it more effective than traditional anticonvulsants like phenytoin for eclampsia. The therapeutic range is 4-8 mEq/L, which provides seizure prophylaxis while minimizing toxicity risk.
What are the side effects of magnesium sulfate?
Common side effects include flushing, warmth, nausea, and diaphoresis from peripheral vasodilation. Serious adverse effects are dose-dependent: loss of deep tendon reflexes at 8-12 mEq/L, respiratory depression above 12 mEq/L, and cardiac arrest above 15 mEq/L. Hypotension can occur from vasodilation. Newborns exposed to maternal magnesium may exhibit hypotonia, respiratory depression, and feeding difficulties transiently. Calcium gluconate 1 gram IV is the antidote for severe toxicity. Monitoring patellar reflexes, respiratory rate, urine output, and serum magnesium levels during infusion is essential.
Why does magnesium sulfate help with torsades de pointes?
Magnesium sulfate terminates torsades de pointes by stabilizing cardiac cell membranes and suppressing early afterdepolarizations, which are the triggered activity responsible for this arrhythmia. Magnesium is essential for normal potassium channel function and helps shorten the prolonged QT interval that predisposes to torsades. Importantly, IV magnesium (2 grams over 1-2 minutes) is effective even in patients with normal serum magnesium levels. It works when other antiarrhythmics fail and is considered first-line therapy for this polymorphic ventricular tachycardia.
When should you not give magnesium sulfate?
Absolute contraindications include myasthenia gravis, where magnesium worsens neuromuscular blockade and can precipitate myasthenic crisis; heart block or significant cardiac conduction abnormalities; and severe renal failure (GFR <30 mL/min) due to impaired elimination and high toxicity risk. Relative contraindications include hypocalcemia, which potentiates magnesium's effects, and concurrent use with neuromuscular blocking agents. If magnesium must be used in renal impairment, drastically reduce doses and monitor serum levels frequently. Always have calcium gluconate available as an antidote when administering IV magnesium.
What is the relationship between magnesium and potassium?
Hypomagnesemia causes refractory hypokalemia that cannot be corrected until magnesium is repleted first. This occurs because magnesium is required for normal function of Na-K-ATPase pumps and renal potassium reabsorption in the thick ascending limb. When magnesium is low, the kidneys waste potassium despite supplementation. Patients on chronic diuretics, those with chronic diarrhea, or alcoholics often have concurrent deficiencies. The clinical pearl: if potassium replacement fails despite adequate dosing, check and correct magnesium levels. Similarly, hypocalcemia may be refractory until magnesium is normalized.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A06AD04WHO ATC/DDD index: A12CC02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.